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A B S T R A C T
It is well-known that humans have used medicinal plants for millennia, but as a defined 
field of scientific research called ethnopharmacology, it has a relatively short history. It 
is linked to the development of pharmacology in the 19th century (as exemplified in the 
work of Claude Bernard linking the explorers’ observations on traditional uses of medicines 
and toxins) and to fascination with psychoactive drugs in the 1960s. This fascination 
gave rise to what we now call ethnopharmacology, a term first used as recently as 1967. 
With thousands of ethnopharmacological articles published each year now, the field has 
expanded greatly. It nowadays covers a wide range of topics based on the anthropological, 
historical and other socio-cultural studies of local and traditional plants, fungi and animals; 
as well as the biological and clinical studies of resources used as medicines, toxins, foods, 
among other applications. It is one of the few fields in science truly transdisciplinary and it 
is a key bridge between socio-cultural and the natural/medical sciences. More importantly, 
ethnopharmacological research is crucial for the improvement of livelihood, health and 
wellbeing of humans.
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Introduction 
There is no doubt that ethnopharmacology is a thriving 
discipline, as now established journals publish thousands 
of articles in this field of research. While there are not many 
institutes carrying the term in their name, many groups 
working in pharmacy, biology, and chemistry, among other 
disciplines, publish in the field. It is impressive for an area of 
study with a surprisingly short history.
Ethnopharmacology is, by definition, a scientific approach 
to the study of the biological activities of any preparation 
used by humans, which have, in a very broad sense, either 
beneficial or toxic or other direct pharmacological effects. As 
such, it is not about describing (generally local or traditional) 
uses, but about the combined broad anthropological and 
pharmacological-toxicological study of these preparations. 
Studies describing the use of useful plants are generally 
included in this definition, but these are generally conducted 
with the goal of leading to an experimental study of botanical 
drugs (Heinrich et al., 2009). 
To the best of our knowledge the term ‘ethnopharmacology’ 
was first used in 1967 by Efron and colleagues who used it 
in the title of a book on hallucinogens: Ethnopharmacological 
Search for Psychoactive Drugs (Efron et al., 1970; Holmstedt, 
1967). This term was proposed much later than the term 
ethnobotany, coined in 1896 by American botanist William 
Harshberger when describing the study of human’ plant 
use. Both ethnopharmacology and ethnobotany investigate 
the relationship between humans and plants in all its 
complexity. Or as Daniel E. Moerman from the University of 
Michigan-Dearborn put it: “Essentially ethnopharmacology is 
the examination of non-Western (not mine) medicinal plant 
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use in terms of Western (my) plant use” (Daniel E. Moerman, 
personal communication, September 15, 2013). Here the 
pharmacological aspect is less at the center. 
It would not be appropriate to limit this discussion to the 
period after 1967. Plants and animal-based medicines are an 
integral part of indigenous medical systems in many regions 
of the world, and form a part of the traditional knowledge of a 
culture. Any study involving the documentation and systematic 
study of local and traditional uses of a plant or taxa is one with 
an ethnopharmacological context. Explorers, missionaries, 
merchants, and knowledgeable experts in the respective 
healing tradition describe the uses of such medicinal plants, 
which may form a basis for ethnopharmacology-based drug 
development. For centuries this knowledge has been widely 
used as a starting point for drug development, and once an 
initial lead is found, many researchers no longer consider this 
knowledge to be of relevance for drug discovery programmes. 
In the context of today’s ethnopharmacology the focus has 
certainly also moved to understand the benefits and risks 
of commonly used local and traditional plants with the aim 
of contributing to a better and safer uses of such resources 
(Heinrich, 2006; 2009).
In a modern biological and biomedical context, 
ethnopharmacology requires an integration of pharmacological, 
or other natural science, approaches with research on local and 
traditional uses. Hence, Claude Bernard (1813-1878), one of the 
founding fathers of pharmacology and physiology, is rightfully 
seen as one of the first researchers to conduct what today we 
would call an ethnopharmacological study. His interest was on 
the study of curare and the reasons behind why it was non-
toxic if applied orally. He wrote (Bernard, 1966): ‘One of the 
facts noted by all those who reported on curare is the lack of 
toxicity of the poison in the gastrointestinal tract. The Indians 
indeed use curare as a poison and as a remedy for the stomach’ 
(p. 93). This is also linked to the way curare is prepared and 
applied. Bernard also stated:‘If curare is applied into a living 
tissue via an arrow or a poisoned instrument, it results in death 
more quickly if it gets into the blood vessels more rapidly. Therefore 
death occurs more rapidly if one uses dissolved curare instead of 
the dried toxin’ (Bernard, 1966: 92). Bernard also was able to 
demonstrate that the animals did not show any nervousness 
and no sign of pain. The main sign of death induced by curare 
is muscular paralysis. If the blood flow in the hind leg of a 
frog is interrupted using a ligature without interrupting the 
innervations, and it is poisoned via an injury of the hind leg, 
it retains its mobility and the animal does not die from curare 
poisoning (p. 115). These and subsequent studies allowed a 
detailed understanding of the pharmacological effects of curare 
on other respiratory paralysis. This is an ethnopharmacological 
analysis of traditional practice using 19th century state-of-the-
art biomedical science. 
The principal compound responsible for this activity was 
isolated for the first time from Chondrodendron tomentosum Ruiz 
and Pav., and in 1947 the structure of the bisbenzylisoquinoline 
alkaloid,  D-tubocurarine was determined. Finally, 
tubocurarine’s structure was resolved using NMR in the 1970 
decade showing that it has only one quaternary nitrogen. 
Currently, in many European countries tubocurarine is 
sporadically used, for example, in France it is still used for 
muscle relaxation during surgery (Heinrich, 2010). In a 
similar argumental line, 19th century research of phantastica 
and hallucinogenic substances played a crucial role in the 
development of psychopharmacolgy/neuropharmacology 
(Holmstedt, 1967)
Any form of empirical use and ‘medical testing’ of a plant 
for novel uses may be considered an ethnopharmacological 
approach. Foxglove, Digitalis purpurea L., Scrophulariaceae, was 
used by an English housewife to treat dropsy currently known 
as edema, and was then explored more systematically for its 
medical properties by the physician William Withering (1741-
1799). He used the orally transmitted knowledge of British 
herbalism in order to develop a medicine used by conventional 
medicine. Prior to such studies, herbalism was more of a 
clinical practice interested in the patient’s welfare, and less 
of a systematic study of the uses and chemical properties of 
medicinal plants. 
These two historical examples are among the many success 
stories of an ethnopharmacology driven drug development 
strategy, albeit the earlier ones were not called so at the 
time.  Numerous other examples could be listed including 
most recent developments on Galanthus spp./Leucojum spp. 
(galanthamine), Croton lechleri Muell. Arg. (Crofelemer), 
Euphorbia peplus L. (Peplin) and Cannabis sativa L. (Sativex®), 
to name just a few examples (Heinrich, 2010). Clearly, natural 
products remain one of the most important sources, even 
maybe the most important one, of new drug leads. More 
than half of new products commercially launched are natural 
products, their derivatives or mimetics (Chin et al., 2006). 
Similar examples could be cited from other medical 
traditions but, more importantly, the above-mentioned 
examples show that the coining of the term ethnopharmacology 
actually offered  focus and a clear concept of a field of research 
interested in the interface of traditional and local medical use 
of plants and their biological characteristics. It also replaced 
the many other terms previously used like Pharmakoëthnologie 
used already by Tschirch (1910) in his classic ‘Handbuch der 
Pharmakognosie’ or pharmacoetnologia or aboriginal botany. 
So how did the term and the concept the term represents 
come about? Even though the term itself is less than 50 years 
old, in fact its origin is not well known as one would expect. 
This article is more than anything a call for more research into 
the short history of this field. A critical appraisal of the term 
would be well warranted. After its initial use in the context 
of hallucinogenic plants the term was only occasionally used 
until 1979, when Laurent Rivier and Jan Bruhn founded the 
Journal of Ethnopharmacology. With this event, the scope was 
broadened to “a multidisciplinary area of research concerned 
with the observation, description, and experimental research 
of indigenous drugs and their biological activity” (Rivier and 
Bruhn, 1979). Thirty-five years later, many journals (including 
the Revista Brasileira de Farmacognosia or Brazilian Journal 
of Pharmacognosy) publish ethnopharmacological research 
and give testimony to the thriving research interest in how 
we humans use plants as medicine, food, as toxins or as a 
veterinary ailment. A much larger share of articles focus on 
the biological and pharmacological activity of locally and 
traditionally used medicinal plants, studies analyzing the 
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local and traditional uses, as well as historical ones, still are 
an important part of what constitutes ‘ethnopharmacology’.
We continue to have a very complex and critical debate 
regarding who benefits from this research and how we 
best follow ethical guidelines, which in this field are most 
prominently, based on the Convention on Biological Diversity 
(Rio Convention, 1992) and subsequent agreements as the 
Nagoya Protocol on Access to Genetic Resources and the Fair 
and Equitable Sharing of Benefits Arising from their Utilization 
(ABS) to the Convention on Biological Diversity (2010). As 
pointed out previously, research in the field is thriving and 
there are tremendous opportunities maybe most importantly 
in the context of developing a rational cientific basis for using 
such local and traditional resources. 
With this development in mind I need to highlight that, 
as in all disciplines, the debate also is very much about what 
constitutes good quality in the field. In this regard we have 
numerous challenges exacerbated by the multidisciplinary 
nature of what today constitutes ethnopharmacology. Thus 
key challenges are often related to scientific precision and 
accuracy; thus ascertaining that the scientific results are 
scientifically reliable and reproducible. I just want to remind 
us of key challenges, and how to achieve them continues to be 
an essential debate (Heinrich and Verpoorte, 2014):
· The botanical authenticity and details about how this was 
achieved needs to be authenticated (e.g. Bennett, 2014; 
Rivera et al., 2014). 
· Ethnopharmacology is about linking local/traditional 
uses with biologic and biomedical studies. Therefore, it is 
crucial to base research on a very sound understanding 
of these uses and the importance of the plants in a 
community (Heinrich et al., 2009) 
· No study makes sense, if it is not supported on a chemical 
and analytical base, and the description of extracts. We 
have particular challenges and as much information as 
possible on an extract and its composition is an essential 
element of all ethnopharmacological studies (e.g. Sheridan 
et al., 2012) 
· There are many challenges in the context of pharmacology, 
but again it is crucial that pharmacological research 
uses state-of-the-art approaches. The models and doses 
used must be of physiological and/or pharmacological 
relevance, and the studies have to be conducted based on 
the existing standards (e.g. Cos et al., 2006; Verspohl, 2002 
among others). One could write pages on what constitute 
minimum standards for pharmacological studies on 
plants. There are trivial points, we all need to remember: 
the proper use of positive and negative controls, the use of 
a dose range which is of pharmacological relevance, and 
appropriate dosing regiments and modes of application 
in in vivo studies.
In essence, the wider challenge lies in the need not 
only to understand, and properly describe, botanical and 
phytochemical aspects of the drugs studied, but also using a 
robust, state-of-the-art and fully reproducible methodology, 
relevant to the question asked. To cite just one of the many 
problems found in literature, a general in silico or in vitro assay 
for antioxidant activity is used and then conclusions are drawn 
on the potential beneficial effects in case of, for example, 
Alzheimer’s disease or other chronic forms of dementia. The 
assays used in this example bear no pharmacological relevance 
for the conditions studied, but provide general data on the 
generic, and thus edibility, anti-oxidant activity of a botanical 
drug. The later is also of scientific interest, but not in the 
context of treating a disease.
Lastly one also needs to consider how much of a 
mechanistic understanding such a study provides and a more 
detailed understanding of the underlying modes of action and 
the drug’s specific targets provides a much better basis for 
evidence-based evaluation than a general screening. 
To conclude this short and very general view on the 
state-of-the-art in ethnopharmacology, we will need to pay 
much more attention to the methods we use and to the 
particular challenges of a multidisciplinary field of research. 
Ethnopharmacology can make very important contributions 
to science and is of interest in practically all countries of 
the world, especially to those undergoing a fast economic 
development and the associated cultural and social changes. 
Consequently, it is our task to make this research meaningful 
and strive for the best practice (Gertsch, 2009). More than 150 
years ago Claude Bernard set such standards, which we need 
to follow in his and other researchers who have formed this 
field tradition. 
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